Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
A cholesterol absorption inhibitor with no anabolic, androgenic or ergogenic action. It exists here as lipid damage control for AAS users. Does not move the natural ceiling. Rated 1 (basically natty).
Overview
The second-line lipid drug: used when a statin alone is not enough, or when statin muscle side effects limit the dose. It works on a completely different mechanism (blocking intestinal cholesterol absorption rather than hepatic synthesis), which is why it stacks additively with a statin rather than overlapping with it.
Important Warnings
- •Contraindicated in active hepatic disease with elevated transaminases and in moderate to severe hepatic impairment
- •Contraindicated in pregnancy and breastfeeding when combined with a statin
- •Rhabdomyolysis risk is concentrated in combination with statins. Report severe muscle symptoms
- •Monotherapy is substantially weaker than a statin (13-20% vs 30-50%+ LDL reduction)
- •Does not restore HDL suppressed by oral steroids
- •Cyclosporine levels require monitoring if co-prescribed
Purpose & Use Cases
Add-On When A Statin Is Not Enough
Its primary role. Adding ezetimibe to a statin produced an additional 24% LDL cholesterol lowering in the IMPROVE-IT trial. Meaningful when androgen-driven LDL elevation is not fully controlled by the statin alone.
Option For Statin-Intolerant Users
For someone who cannot tolerate an effective statin dose because of muscle symptoms, ezetimibe monotherapy delivers a 13% to 20% LDL-C reduction with a much lighter side-effect profile.
Benefits
- Monotherapy lowers LDL-C by 13% to 20%
- Added to a statin, lowered LDL cholesterol by a further 24% in IMPROVE-IT
- IMPROVE-IT, in over 18,000 acute coronary syndrome patients, showed a 2% lower risk of cardiovascular events when added to statin therapy
- Mechanism is completely independent of statins, so the effects are additive rather than overlapping
- Notably mild side-effect profile: most common complaints are headache, runny nose and sore throat
- Once daily, with or without food
Good to Know
Different mechanism is the whole value proposition
Statins reduce how much cholesterol the liver makes. Ezetimibe reduces how much the gut absorbs. Because those are separate pathways, the effects add rather than overlap, which is why the combination is standard practice rather than redundancy.
The IMPROVE-IT numbers in context
In more than 18,000 acute coronary syndrome patients, adding ezetimibe to simvastatin lowered LDL cholesterol by 24% and reduced cardiovascular event risk by 2%. The LDL number is large; the outcome number is modest. Both are true, and quoting only one of them misrepresents the drug.
The statin-intolerant fallback
Monotherapy delivers 13-20% LDL reduction: clearly less than a statin, but with a much lighter side-effect burden. For someone who genuinely cannot tolerate statin muscle symptoms, that is the realistic alternative rather than doing nothing.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 10 – 10 mg/day |
| Intermediate | 10 – 10 mg/day |
There is effectively no dose-ranging decision here: 10mg daily is the standard and only dose. Higher doses do not add benefit, which makes this one of the simplest drugs in the archive to run correctly. Like any lipid intervention it is dosed against a measured lipid panel, and its role is usually as an add-on to a statin rather than a standalone.
Peak plasma concentrations are reached within 4-12 hours and protein binding exceeds 90%. The long half-life supports simple once-daily dosing with or without food.
Side Effects
Headache, rhinitis, sore throat
commonThe most commonly reported effects, and mild.
Generally self-limiting.
Body aches, back pain, diarrhea, fatigue
uncommonLess frequently reported effects.
Usually tolerable; discontinue if persistent.
Rhabdomyolysis
rareSerious but rare, and the risk is concentrated in combination with statins rather than with ezetimibe alone.
Seek medical attention for severe unexplained muscle pain, weakness or dark urine. Monitor for myopathy signs when combined with a statin.
Hepatotoxicity
rareIncluding autoimmune hepatitis. Relevant when stacked with hepatotoxic oral steroids or a statin.
Liver function tests at baseline and during therapy.
General Mitigation Strategies
This is a mild drug by the standards of anything else in this archive. The routine complaints are headache and upper-respiratory symptoms. The two things that need watching are myopathy when it is combined with a statin, and liver function when it is layered on top of hepatotoxic oral compounds. Monitoring is a baseline and periodic lipid panel plus liver function tests.
Support Supplements
Ancillary supplements commonly run alongside Ezetimibe to manage side effects, support the target tissue, or fill nutrient demands it creates.
Lipid panel + liver function bloodwork
KeyLipid drugs are dosed to a measured target; liver function matters when stacked with oral steroids or a statin
- Timing
- Baseline and periodically
Post Cycle Therapy (PCT)
No HPT axis interaction. No PCT implications.
How It Works
Ezetimibe inhibits cholesterol absorption at the small intestine brush border by blocking the sterol transporter Niemann-Pick C1-Like-1 (NPC1L1). Less dietary and biliary cholesterol reaches the liver, which reduces hepatic cholesterol stores and increases clearance of cholesterol from the blood. Because a statin works by suppressing hepatic synthesis, the two mechanisms are genuinely complementary.
Hormonal & Androgenic Profile
N/A: not an androgen.
Not a hormonal drug.
Protective. Lowers LDL by blocking intestinal absorption, additive with a statin. Like statins, it does not restore AAS-suppressed HDL.
Fundamentals
Reference on the practices relevant to Ezetimibe: how they are done and where they go wrong. Not a recommendation to use it.
Common Stacks
- Ezetimibe + Rosuvastatin: the standard additive lipid combination
- Ezetimibe monotherapy for statin-intolerant users, accepting the smaller 13-20% reduction
- Ezetimibe alongside harsh oral cycles as part of a broader lipid protocol
Legal Status
FDA-approved for hyperlipidemia, as monotherapy or added to a statin. Not a controlled substance.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
A lipid-lowering medication with no performance-enhancing action. Not listed on the WADA Prohibited List.